Long-term outcomes of persistent disease and relapse in primary membranous nephropathy

Nephrology Dialysis Transplantation

Volumn 31, Issue 12, 2016, Pages 2108-2114

  Kanigicherla, Durga A K ^a,b   Short, Colin D ^a   Roberts, Stephen A ^c   Hamilton, Patrick ^a   Nikam, Milind ^a   Harris, Shelley ^a   Brenchley, Paul E C ^a   Venning, Michael C ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Active disease; CKD 5; Primary membranous nephropathy; Relapse

Indexed keywords

ADULT; AGED; ARTICLE; BIOPSY; DEATH; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SURVIVAL; ADOLESCENT; DISEASE COURSE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULUS FILTRATION RATE; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85027715704     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv435     Document Type: Article

References (33)

1. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomer-ulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430
2. Donadio JV, Jr., Torres VE, Velosa JA et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988; 33: 708-715
3. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89
4. Marx BE, Marx M. Prediction in idiopathic membranous nephropathy. Kidney Int 1999; 56: 666-673
5. Branten AJ, du Buf-Vereijken PW, Klasen IS et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16: 169-174.
6. Kanigicherla D, Gummadova J, McKenzie E et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013; 83: 940-948
7. Troyanov S, Wall CA, Miller JA et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004; 66: 1199-1205
8. Waldman M, Austin HA, III. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2005; 23: 1617-1630
9. Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005; 16: 1188-1194
10. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 1999; 56: 1534-1543
11. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490
12. Jha V, Ganguli A, Saha TK et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899-1904.
13. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450
14. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604
15. Ruggenenti P, Cravedi P, Chianca A et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-1425
16. Ruggenenti P, Cravedi P, Remuzzi G. Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother 2007; 8: 3159-3171
17. Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381: 744-751
18. Group KDIGOKGW. KDIGO Clinical Practice Guideline for Glomerulo-nephritis. Kidney Int Suppl 2012; 2012: 139-274
19. van den Brand JA, van Dijk PP, Hofstra JM et al. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 2014; 25: 150-158
20. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254
21. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2014. http://www.R-projgect.org/)
22. Aaltonen S, Honkanen E. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy. Nephrol Dial Transplant 2011; 26: 2871-2877
23. McQuarrie EP, Stirling CM, Geddes CC. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy. Nephrol Dial Transplant 2012; 27: 235-242
24. Polanco N, Gutierrez E, Covarsi A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704
25. Glassock RJ. Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach. Clin J Am Soc Nephrol 2014; 9: 1341-1343
26. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004; 19: 1142-1148
27. Brenchley PE. Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of anti-phospholipase A2 receptor autoantibodies. J Am Soc Nephrol 2015; 26: 2308-2311
28. Ruggenenti P, Debeic H, Ruggiero B et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 2015; 26: 2545-2558
29. Branten AJ, Reichert LJ, Koene RA et al. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 1998; 91: 359-366
30. Falk RJ, Hogan SL, Muller KE et al. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med 1992; 116: 438-445
31. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002; 100: 82-85
32. Travis LB, Curtis RE, Glimelius B et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524-530
33. Morton M, Edmonds S, Doherty AM et al. Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement. Rheumatol Int 2012; 32: 3373-3382.